Myriad (MYGN), Teva's Cephalon Enter BRCA Mutation Testing Agreement
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Join SI Premium – FREE
Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company (Nasdaq: TEVA), to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study.
Under the agreement, Myriad will assess the BRCA status in patients prior to being enrolled in the study. Myriad has entered into similar agreements with Abbott Pharmaceuticals (NYSE: ABT), Astra Zeneca (NYSE: AZN) and BioMarin Pharmaceuticals (Nasdaq: BMRN) to provide companion diagnostic testing with the BRACAnalysis® test for clinical trial enrollment.
Under the agreement, Myriad will assess the BRCA status in patients prior to being enrolled in the study. Myriad has entered into similar agreements with Abbott Pharmaceuticals (NYSE: ABT), Astra Zeneca (NYSE: AZN) and BioMarin Pharmaceuticals (Nasdaq: BMRN) to provide companion diagnostic testing with the BRACAnalysis® test for clinical trial enrollment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- CoVolt Power files for proposed IPO
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
